Moderna Inc.
MRNA,
said Thursday its COVID-19 vaccine Spikevax was approved by Health Canada for use in children aged six months to five years. The biotechnology company said the two-dose regimen for children in that age group is completed in one month, the same as for adults, adolescents and children over five years old. Moderna’s vaccine was authorized in the U.S. last month for use in that age group. Moderna’s stock, which slumped 5.1% in midday trading, has slipped 1.8% over the past three months, while the iShares Biotechnology ETF
IBB,
has lost 7.1% and the S&P 500
SPX,
has dropped 14.3%.
[ad_1]
[ad_2]
Image and article originally from www.marketwatch.com. Read the original article here.